Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results

Journal of Clinical Oncology

Volumn 33, Issue 12, 2015, Pages 1356-1363

  Morris, Michael J ^a   Molina, Arturo ^a   Small, Eric J ^c   De Bono, Johann S ^d   Logothetis, Christopher J ^e   Fizazi, Karim ^f   De Souza, Paul ^g   Kantoff, Philip W ^h   Higano, Celestia S ⁱ   Li, Jinhui ^j   Kheoh, Thian ^b   Larson, Steven M ^a   Matheny, Shannon L ^b   Naini, Vahid ^b   Burzykowski, Tomasz ^k   Griffin, Thomas W ^b   Scher, Howard I ^a   Ryan, Charles J ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITY OF WESTERN SYDNEY   (Australia)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j Analytical Research and Development Process and Product Scientific Solutions Johnson and Johnson   (United States)

^k INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; BIOLOGICAL MARKER; PREDNISONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; BONE SCINTISCANNING; CANCER PATIENT; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RADIOGRAPHIC PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; TREATMENT RESPONSE; BONE TUMOR; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME;

ABIRATERONE ACETATE; ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; MALE; NEOPLASM METASTASIS; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84925322822     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.3875     Document Type: Article

References (26)

1. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
2. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
3. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
4. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012
5. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
6. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
7. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197,2012
8. Scher HI, Morris MJ, Kelly WK, et al: Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 11:5223-5232, 2005
9. Halabi S, Vogelzang NJ, Ou SS, et al: Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 27:2766-2771, 2009
10. Scher HI, Warren M, Heller G: The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 13:1488-1492, 2007
11. FDA Oncologic Drugs Advisory Committee Meeting on Prostate Cancer Endpoints, Bethesda, MD, March 3, 2005. http://www.fda.gov/Drugs/Development ApprovalProcess/DevelopmentResources/Cancer Drugs/ucm094586.htm
12. Scher HI, Halabi S, Tannock I, et al: The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer. J Clin Oncol 31:321s, 2013 (suppl 15s; abstr 5057)
13. Fox JJ, Morris MJ, Larson SM, et al: Developing imaging strategies for castration resistant prostate cancer. Acta Oncol 50:39-48, 2011
14. Morris MJ, Farrelly JS, Fox JJ, et al: The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload. J Clin Oncol 29, 2011 (suppl; abstr 121)
15. Carducci MA, Saad F, Abrahamsson PA, et al: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110: 1959-1966, 2007
16. Sternberg CN, Petrylak DP, Sartor O, et al: Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 27:5431-5438, 2009
17. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
18. Burzykowski T, Molenberghs G, Buyse M, et al: Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J Roy Stat Soc: Series C (Appl Stat) 50:405-422, 2001
19. US Food and Drug Administration: FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting July 24, 2012-Examination of Radiologic Review of Progression-Free Survival in Non- Hematologic Malignancies. http://www.fda.gov/downloads/advisorycommittees/committeesmeeting materials/drugs/oncologicdrugsadvisorycommittee/ucm311141.pdf
20. US Food and Drug Administration: Abiraterone acetate. http://www.fda.gov/Drugs/InformationOn Drugs/ApprovedDrugs/ucm331628.htm
21. European Medicines Agency: Zytiga. http://www.ema.europa.eu/ema/index.jsp?curlôpages/medicines/human/medicines/002321/human- med-001499.jsp&midôWC0b01ac058001d124
22. Kluetz PG, Ning YM, Maher VE, et al: Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 19:6650-6656, 2013
23. US Food and Drug Administration: FDA Briefing Document: Oncology Drugs Advisory Committee Meeting July 24, 2007-NDA 21801 Orplatna (satraplatin capsules). http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4309b1-04-fda.pdf
24. Woodcock J, Woosley R: The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1-12, 2008
25. Ryan CJ, Shah S, Efstathiou E, et al: Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17:4854-4861, 2011
26. Gignac GA, Morris MJ, Heller G, et al: Assessing outcomes in prostate cancer clinical trials: A twenty-first century tower of Babel. Cancer 113: 966-974, 2008